Hong Kong stock market anomaly | Keji Pharmaceutical-B (02171.HK) rose nearly 3%, the summary of the trial results of Shurui Jialunsi Injection for the adjuvant treatment of pancreatic cancer will be presented at ESMO.
According to the Securities Times app, Keji Pharmaceutical-B (02171.HK) has risen nearly 3%, as of the time of publication, it has risen 1.84%, to HK$24.9, with a trading volume of HK$20.068 million.
Latest
